Johnson & Johnson
NYSE:JNJ

  • LAST PRICE
    145.6900
  • TODAY'S CHANGE (%)
    -0.3400 (-0.2328%)
  • Bid / Lots
    145.5000/ 5
  • Ask / Lots
    145.8900/ 10
  • Open / Previous Close
    146.2000 / 146.0300
  • Day Range
    144.7400
    146.6500
  • 52 Week Range
    143.1300
    175.9700
  • Volume
    3,243,075

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 3 hours ago by MT Newswires
      Companies Mentioned: JNJ
      10:29 AM EDT, 07/03/2024 (MT Newswires) -- Johnson & Johnson (JNJ) said Wednesday that Health Canada has approved Rybrevant in combination with platinum-based chemotherapy to treat adults with locally advanced or metastatic non-small cell lung cance...

    • 5 hours ago by Dow Jones
      Companies Mentioned: JNJ

      By Michael Susin

      Johnson & Johnson said the Canadian health authority issued a notice of compliance for its lung-cancer treatment, meaning the drug is authorized to be marketed under certain conditions.

    • 5 hours ago by Dow Jones
      Companies Mentioned: JNJ

      This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of RYBREVANT(R) (amivantamab). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Janssen Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

  • Yesterday

      Show headlines and story abstract

    • 7:56AM ET on Tuesday Jul 02, 2024 by MT Newswires
      Companies Mentioned: JNJ
      07:56 AM EDT, 07/02/2024 (MT Newswires) -- Johnson & Johnson (JNJ) said on Tuesday interim analysis of the Phase 3 study of its experimental therapy, Carvykti, to treat certain patients with a type of blood cancer showed a statistically significant ...

    • 7:30AM ET on Tuesday Jul 02, 2024 by Dow Jones
      Companies Mentioned: JNJ

      This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development of CARVYKTI(R) . The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Biotech, Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory actions; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Biotech, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Peers Headlines